Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Connie Cook

Physician Assistant, Medical Man, WV Physician Assistant

NPI 1164426128 CMS profile 10888468

114 Main St, Man, WV 25635

Open in the dashboard

General payments

$3,873

255 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Connie Cook of Man, WV is reported in the CMS Open Payments database as having received $3,873 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $754 58
2024 General $745 40
2023 General $847 53
2022 General $314 18
2021 General $1,212 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Connie Cook
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Connie Cook were reported at $754. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Connie Cook Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,212 $156 $41–$563 $132
2022 $314 $185 $55–$649 $149
2023 $847 $199 $58–$717 $160
2024 $745 $206 $62–$740 $164
2025 $754 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $552 34 payments
  2. AstraZeneca Pharmaceuticals LP $458 29 payments
  3. Pfizer Inc. $453 47 payments
  4. AbbVie, Inc. $427 24 payments
  5. Novo Nordisk Inc $347 19 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $241 19 payments
  7. Sumitomo Pharma America, Inc. $209 13 payments
  8. Abbott Laboratories $177 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $163 11 payments
  10. Lilly USA, LLC $160 9 payments
  11. Other $684 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,873 255 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $540 33 payments
  2. FARXIGA $382 24 payments
  3. Ozempic $333 18 payments
  4. RYBELSUS $316 17 payments
  5. VRAYLAR $294 16 payments
  6. XIFAXAN $241 19 payments
  7. COLOGUARD DNA CAPTURE REAGENTS $240 18 payments
  8. GEMTESA $209 13 payments
  9. NURTEC ODT $189 27 payments
  10. FreeStyle Libre 2 $177 9 payments
  11. Other $2,116 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

11,342

Median for Physician Assistant: 241

Drug cost

$553,836

Median for Physician Assistant: $4,110

Branded share of claims

21.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 78 $86,757
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 85 $65,273
Mounjaro Tirzepatide Brand 39 $44,342
Jardiance Empagliflozin Brand 51 $42,164
Farxiga Dapagliflozin Propanediol Brand 48 $41,764
Eliquis Apixaban Brand 46 $33,867
Trulicity Dulaglutide Brand 31 $28,197
Brilinta Ticagrelor Brand 21 $17,106
Entresto Sacubitril/Valsartan Brand 20 $16,821
Vascepa Icosapent Ethyl Brand 21 $13,935

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $77
$77 — —
VRAYLAR
  • AbbVie, Inc. $74
$74 — —
RYBELSUS
  • Novo Nordisk Inc $66
$66 — —
Ozempic
  • Novo Nordisk Inc $66
$66 78 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record